Immunity and vaccine control of Echinococcus granulosus infection in animal intermediate hosts.

摘要: Much progress has been made with characterisation of the EG95 vaccine which can be used to prevent hydatid infection in animal intermediate hosts Echinococcus granulosus. The comprises a single recombinant oncosphere antigen and adjuvant Quil A. It induces complement-fixing antibodies that kill invading early an infection. In majority vaccinated animals, no cysts occur following challenge However, small number viable may some animals. proved effective trials carried out sheep New Zealand, Australia, Argentina, Chile China as well goats cattle. Investigations genetic diversity gene encoding have identified unequivocal variation within G1 strain parasites; however DNA sequence family genes found G6/G7 parasites. GMP production scale-up undertaken Zealand it is expected will become available through these sources for implementation part control programs worldwide.